Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
22/09/2026 13:00
BRIEF-Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint Sept 22 (Reuters) - Otsuka Pharmaceutical:
OTSUKA PHARMACEUTICAL: PHASE 3 FUSION RESULTS FOR ULEFNERSEN MET PRIMARY ENDPOINT
OTSUKA PHARMACEUTICAL: ULEFNERSEN SHOWED STATISTICALLY SIGNIFICANT IMPROVEMENT IN ENDPOINT FOR FUNCTIONAL IMPAIRMENT, SURVIVAL IN STUDY FOR FUS-ALS
OTSUKA PHARMACEUTICAL: ULEFNERSEN DEMONSTRATED FAVORABLE SAFETY & TOLERABILITY PROFILE WITH MOST ADVERSE EVENTS BEING MILD OR MODERATE IN SEVERITY
Further company coverage: 4578.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug